Skip to main content

Table 1 Clinicopathological characteristics of SKCM patients

From: Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients

Characteristics

FAHSU cohort (N = 46)

GEO cohort (N = 93)

TCGA cohort (N = 472)

N (%)

 Age

   ≤ 60 years

21 (45.6)

53 (56.9)

258 (54.7)

   > 60 years

25 (54.4)

40 (43.1)

214 (45.3)

 Gender

  Male

30 (65.2)

55 (59.1)

297 (61.9)

  Female

16 (34.8)

38 (40.9)

183 (38.1)

 Clark level

  I

6 (13.0)

13 (13.9)

6 (1.8)

  II

25 (54.3)

25 (26.8)

18 (5.5)

  III–IV

12 (26.1)

47 (50.7)

246(75.5)

  V

3 (6.6)

8 (8.6)

56 (17.2)

 Breslow depth(mm)

  ≤ 0.75

5 (10.9)

15 (16.1)

36 (10.2)

  0.76–1.50

28 (60.9)

30 (32.2)

65 (18.4)

  1.51–4.00

11 (23.9)

39 (41.9)

106 (30.0)

  > 4.00

2 (4.3)

9 (9.8)

146 (41.4)

 pT stage

  T1–T2

32 (69.6)

57 (61.3)

121 (32.7)

  T3–T4

14 (30.4)

36 (38.7)

249 (67.3)

 pN stage

  N0

46 (100)

93 (100)

236 (65.0)

  N1

0 (0)

0 (0)

75 (20.7)

  N2

0 (0)

0 (0)

52 (14.3)

 pM stage

  M0

46 (100)

93 (100)

424 (94.4)

 M1

0 (0)

0 (0)

25 (5.6)

 Pathologic stage

  I–II

46 (100)

93 (100)

233 (53.9)

  III–IV

0 (0)

0 (0)

199 (46.1)

 Persistent distant metastasis

  No

46 (100)

93 (100)

217 (46.1)

  Yes

0 (0)

0 (0)

254 (53.9)

  1. SKCM, Skin Cutaneous Melanoma
  2. FAHSU, The First Affiliated Hospital of Soochow University
  3. GEO, The Gene Expression Omnibus
  4. TCGA, The Cancer Genome Atlas